The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

被引：0
|
作者：
Stevenson, Robert
Ford, Daniel
Zarkar, Anjali M.
Glaholm, John
Porfiri, Emilio
Tew, Alice
El-Modir, Ahmed
James, Nicholas David
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[4] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[5] Univ Birmingham, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16048
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven UK centers.
    Stevenson, Robert
    Fackrell, David Gareth
    Ford, Daniel
    Glaholm, John
    El-Modir, Ahmed
    Porfiri, Emilio
    Zarkar, Anjali M.
    Tanguay, Jacob
    Rackley, Thomas
    James, Nicholas David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Enzalutamide (formerly MDV3100) prolongs survival in docetaxelpretreated castration-resistant prostate cancer patients
    Heck, Matthias M.
    Gschwend, Juergen E.
    Retz, Margitta
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2013, 2 (02) : 92 - 93
  • [3] Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100
    Ileana, Ecaterina
    Loriot, Yohann
    Albiges, Laurence
    Massard, Christophe
    Blesius, Aurore
    Di Palma, Mario
    Escudier, Bernard J.
    Blanchard, Pierre
    Bossi, Alberto
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
    Bianchini, D.
    Lorente, D.
    Rodriguez-Vida, A.
    Omlin, A.
    Pezaro, C.
    Ferraldeschi, R.
    Zivi, A.
    Attard, G.
    Chowdhury, S.
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 78 - 84
  • [5] Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
    Loriot, Y.
    Bianchini, D.
    Ileana, E.
    Sandhu, S.
    Patrikidou, A.
    Pezaro, C.
    Albiges, L.
    Attard, G.
    Fizazi, K.
    De Bono, J. S.
    Massard, C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1807 - 1812
  • [6] Antitumor activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
    Massard, C.
    ONCOLOGIE, 2013, 15 (10-11) : 543 - 544
  • [7] Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment
    Badrising, Sushil
    van der Noort, Vincent
    van Oort, Inge M.
    van den Berg, H. Pieter
    Los, Maartje
    Hamberg, Paul
    Coenen, Jules L.
    van den Eertwegh, Alfons J. M.
    de Jong, Igle J.
    Kerver, Emile D.
    van Tinteren, Harm
    Bergman, Andries M.
    CANCER, 2014, 120 (07) : 968 - 975
  • [8] Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100
    Efstathiou, Eleni
    Titus, Mark
    Tsayachidou, Dimitra
    Wen, Sijin
    Hoang, Anh
    Ashe, Robynne
    Karlou, Maria
    Berman, Craig
    Troncoso, Patricia
    Mohler, James
    Logothetis, Christopher J.
    CANCER RESEARCH, 2012, 72
  • [9] ABIRATERONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL AND MDV3100: A MULTICENTRE STUDY
    Bianchini, D.
    Loriot, Y.
    Ileana, E.
    Sandhu, S.
    Pezaro, C.
    Albiges, L.
    Attard, G.
    Fizazi, K.
    de Bono, J. S.
    Massard, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 304 - 305
  • [10] Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (06) : 805 - 806
12345